Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1244]

Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for...

Dr Silvia Novello - University of Turin, Turin, Italy

Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Lenvatinib remains standard of care for first-line therapy in advanced...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC...

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

Lasofoxifene shows promise for women with ESR1-mutated mBC

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Lasofoxifene shows promise for women with ESR1-mutated mBC ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

New data presented at ESMO for multi-cancer early detection

Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences

New data presented at ESMO for multi-cancer early detection ( Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences )

Perioperative nivolumab did not improve RFS in RCC patients at high risk for...

Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA

Perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence ( Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA )

Nirogacestat demonstrates clinically significant improvement in PFS versus...

Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany

Nirogacestat demonstrates clinically significant improvement in PFS versus placebo for progressing desmoid tumours ( Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany )

Scientists discover mechanism of action and an actionable inflammatory axis for...

Prof Charles Swanton - The Francis Crick Institute, London, UK

Scientists discover mechanism of action and an actionable inflammatory axis for air pollution induced NSCLC ( Prof Charles Swanton - The Francis Crick Institute, London, UK )

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly...

Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly improved PFS for advanced melanoma ( Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )

Cervical cancer programme in Kenya: lessons to guide elimination as a public...

Dr Valerian Mwenda - Ministry of Health, Nairobi, Kenya

Cervical cancer programme in Kenya: lessons to guide elimination as a public health problem ( Dr Valerian Mwenda - Ministry of Health, Nairobi, Kenya )

An overview of treatment advances in gastric cancer

Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA

An overview of treatment advances in gastric cancer ( Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA )

More from ecancer